Free Trial

Moody Lynn & Lieberson LLC Buys 861 Shares of Stryker Corporation $SYK

Stryker logo with Medical background

Key Points

  • Moody Lynn & Lieberson LLC increased its stake in Stryker Corporation by 1.0%, adding 861 shares to own a total of 87,798 shares, which are valued at approximately $34.7 million.
  • Stryker reported a quarterly earnings per share (EPS) of $3.13, exceeding analyst estimates, with revenues of $6.02 billion indicating an 11.1% year-over-year growth.
  • The company announced a quarterly dividend of $0.84 per share, reflecting a dividend yield of 0.9%, with a payout ratio of 44.50%.
  • Interested in Stryker? Here are five stocks we like better.

Moody Lynn & Lieberson LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 87,798 shares of the medical technology company's stock after purchasing an additional 861 shares during the quarter. Stryker accounts for about 2.0% of Moody Lynn & Lieberson LLC's investment portfolio, making the stock its 17th biggest position. Moody Lynn & Lieberson LLC's holdings in Stryker were worth $34,736,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in SYK. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the 1st quarter worth approximately $32,000. City Holding Co. lifted its position in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC boosted its stake in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock worth $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new stake in Stryker in the 1st quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker in the 1st quarter valued at $40,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of Stryker stock opened at $368.83 on Monday. The firm has a 50 day simple moving average of $385.71 and a 200 day simple moving average of $379.18. The firm has a market cap of $141.01 billion, a P/E ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.During the same quarter in the prior year, the firm posted $2.81 earnings per share. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SYK. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Needham & Company LLC upped their price objective on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. BTIG Research reissued a "buy" rating on shares of Stryker in a report on Monday, July 14th. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price target on the stock. Finally, Rothschild Redb upgraded Stryker to a "hold" rating in a research note on Thursday, September 18th. Fourteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $430.33.

Read Our Latest Research Report on SYK

Insider Activity

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.